US › Healthcare

Intelligent Bio Solutions Inc. (INBS)

US · Healthcare · Medical Devices

$1.50+4.17%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Revenue YoY

+35.8%

Net profit

$-3.9M

EPS

$-0.90

EPS estimate

$-1.58

Net margin

-341.0%

EPS came in at -0.90 against a street estimate of -1.58 — a beat of 43.0%.

Key statistics

Market cap

$4.8M

Forward P/E

0.0

P/B

1.07

Book value

$1.90

EPS (TTM)

$-8.44

52-week high

$24.90

52-week low

$1.35

50-day MA

$2.09

200-day MA

$3.79

Beta

4.30

Analyst view

Analysts rate Intelligent Bio Solutions Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

2.73%

Institutions

5.47%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	4.26%
Geode Capital Management, LLC	0.63%
Vanguard Capital Management, LLC	0.18%
UBS Group AG	0.17%
Vanguard Fiduciary Trust Co	0.12%
Tower Research Capital LLC	0.10%
Advisor Group Holdings, Inc.	0.01%
Barclays PLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Intelligent Bio Solutions Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.